» Articles » PMID: 30165345

Structure-activity Relationship and Pharmacokinetic Studies of 3-O-substitutedflavonols As Anti-prostate Cancer Agents

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2018 Aug 31
PMID 30165345
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Thirty-eight 3-O-substituted-3',4'-dimethoxyflavonols and twenty-five 3-O-substituted-3',4',7-trimethoxyflavonols have been synthesized for systematic investigation on the structure-activity relationships of 3-O-substituted-3',4'-dimethoxyflavonols in three human prostate cancer cell models. Our findings indicate that incorporation of an appropriate amino group to 3-OH of 3',4'-dimethoxyflavonol and 3',4',7-trimethoxyflavonol through a 3- to 5-carbon linker can substantially improve the in vitro antiproliferative potency in three human prostate cancer cell models, but not in two non-neoplastic human epithelial cell models (MCF 10A and PWR-1E). 1-Methylpiperazine, pyrrolidine, and dibutylamine are optimal terminal amine groups that, in combination with a 3- to 5-carbon linker, are notably beneficial to the anti-proliferative potency of 3-O-substituted-3',4'-dimethoxyflavonols. It is worth noting that 3-O-(4-methylpiperazin-1-yl)propyl-3',4',7-trimethoxyflavonol (76) induces PC-3 cell death in a completely different way from 3-O-pyrrolidinopentyl-3',4',7-trimethoxyflavonol (81) even though they belong to 3-O-substituted-3',4',7-trimethoxyflavonols and exhibit similar potency in inhibiting PC-3 cell proliferation, suggesting that the mechanism of action for each specific 3-O-substitutedflavonol varies with different amino moiety. 3-O-(N,N-Dibutylamino)propyl-3',4'-dimethoxyflavonol (42) emerged as the most promising derivative due to its substantially improved potency in cell models, superior bioavailability in rats, and good selectivity of inhibiting prostate cancer cell proliferation over non-neoplastic human epithelial cell proliferation.

Citing Articles

A Facile Route to Flavone-3-Carboxamides and Flavone-3-Carboxylates via Palladium-Catalyzed Amino- and Aryloxy-Carbonylation Reactions.

Chniti S, Kollar L, Benyei A, Dornyei A, Takacs A Int J Mol Sci. 2024; 25(18).

PMID: 39337616 PMC: 11432944. DOI: 10.3390/ijms251810128.


Flavones and Related Compounds: Synthesis and Biological Activity.

Leonte D, Ungureanu D, Zaharia V Molecules. 2023; 28(18).

PMID: 37764304 PMC: 10535985. DOI: 10.3390/molecules28186528.


In-silico activity prediction and docking studies of some flavonol derivatives as anti-prostate cancer agents based on Monte Carlo optimization.

Tajiani F, Ahmadi S, Lotfi S, Kumar P, Almasirad A BMC Chem. 2023; 17(1):87.

PMID: 37496005 PMC: 10373329. DOI: 10.1186/s13065-023-00999-y.


The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells.

Zarmouh N, Messeha S, Mateeva N, Gangapuram M, Flowers K, Eyunni S Molecules. 2020; 25(9).

PMID: 32403270 PMC: 7249060. DOI: 10.3390/molecules25092257.

References
1.
HARBORNE J, Williams C . Advances in flavonoid research since 1992. Phytochemistry. 2000; 55(6):481-504. DOI: 10.1016/s0031-9422(00)00235-1. View

2.
Dias T, Duarte C, Lima C, Proenca M, Pereira-Wilson C . Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin. Eur J Med Chem. 2013; 65:500-10. DOI: 10.1016/j.ejmech.2013.04.064. View

3.
Geybels M, Verhage B, Arts I, van Schooten F, Goldbohm R, van den Brandt P . Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer. Am J Epidemiol. 2013; 177(12):1388-98. DOI: 10.1093/aje/kws419. View

4.
Saad S, Jones D, Norris L, Horner-Glister E, Patel K, Britton R . Tissue distribution and metabolism of the putative cancer chemopreventive agent 3',4',5'-trimethoxyflavonol (TMFol) in mice. Biomed Chromatogr. 2012; 26(12):1559-66. DOI: 10.1002/bmc.2732. View

5.
KAIGHN M, Narayan K, Ohnuki Y, Lechner J, Jones L . Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979; 17(1):16-23. View